All In Biotech

Drug Trial Radar · NCT02651220

Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Jun 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,001 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,001

Actual

Start

Nov 2015

Primary completion

Apr 2016

Study completion Oct 2016

Sponsor

Lead sponsor
Actavis Inc.Industry
Sponsor type
Industry
First posted
Jan 8, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of adapalene and benzoyl peroxide gel, 0.3%/2.5% (Actavis Laboratories UT, Inc.) to Epiduo® Forte (adapalene and benzoyl peroxide) gel 0.3%/2.5% (Galderma) in the treatment of Acne Vulgaris

Conditions

  • Acne

Interventions

  • Epiduo® Forte GelDrug

    Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w

  • Adapalene and Benzoyl Peroxide GelDrug

    Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w

  • placebo gelDrug

    vehicle used as placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline to Week 12 in the Number of Inflamed Lesions.Time frame: 12 weeks
  2. Percent Change From Baseline to Week 12 in the Number of Non-inflamed Lesions.Time frame: 12 weeks

Locations

20 sites in 2 countries. Site status is shown where the registry gives one.

  • Site 103

    Mesa, Arizona

  • Site 109

    Tucson, Arizona

  • Site 112

    Anaheim, California

  • Site 110

    Long Beach, California

  • Site 111

    Los Angeles, California

  • Site 104

    San Diego, California

  • Site 113

    West Covina, California

  • Site 101

    Brandon, Florida

  • Site 119

    Jacksonville, Florida

  • Site 114

    Miami, Florida

  • Site 115

    Miami, Florida

  • Site 116

    Miramar, Florida

  • Site 102

    Arlington Heights, Illinois

  • Site 105

    Carmel, Indiana

  • Site 120

    New Albany, Indiana

  • Site 107

    Henderson, Nevada

  • Site 106

    High Point, North Carolina

  • Site 108

    Rhinelander, Wisconsin

  • Site 117

    Belize City, Belize

  • Site 118

    Belize City, Belize

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.